Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone.

Slides:

Advertisements

Similar presentations

Long-term outcome of patients in the LNH-98

Advertisements

Advances in the Management of Relapsed/Refractory Multiple Myeloma

1. 2 Lenalidomide in Newly Diagnosed Multiple Myeloma Clinical Update EHA 2010 DR. OUSSAMA JRADI.

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

CARFILZOMIB IFM MARS 2015.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

Michel Attal, M.D., Valerie Lauwers-Cances, M.D., Gerald Marit, M.D., Denis Caillot, M.D., Philippe Moreau, M.D., Thierry Facon, M.D., Anne Marie Stoppa,

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm,

Volume 370, Issue 9594, Pages (October 2007)

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year.

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Mateos MV et al. Proc ASH 2013;Abstract 403.

Realistic Lenalidomide Dose Adjustment Strategy for Transplant-Ineligible Elderly Patients with Relapsed/Refractory Multiple Myeloma: Japanese Real-World.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura by Miguel Hie, Julie Gay, Lionel.

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

How I treat extramedullary myeloma

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Attal M et al. Proc ASCO 2010;Abstract 8018.

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy by Caroline Besson, Aicha Goubar, Jean Gabarre, Willy Rozenbaum,

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen.

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease by Florence Magrangeas, Valéry.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on.

The role of complete response in multiple myeloma

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia by Yves Chalandon, Xavier.

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

Protease inhibitors potentiate chemotherapy-induced neutropenia

CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study.

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma by Weiyun Z. Ai, Robert Tibshirani, Behnaz.

by Michael F. Leahy, and J. Harvey Turner

Randomized comparison of double induction and timed-sequential induction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia.

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma by Pier Luigi Zinzani, Vincent.

Response to Carfilzomib Therapy

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Overall survival by SCT versus observation in first complete remission

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD by Gérard Socié, Noel Milpied, Ibrahim.

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Volume 65, Issue 2, Pages (February 2004)

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study by Shaji Kumar, Ravi Vij, Jonathan L.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Twenty-Year Follow-Up of a Controlled Trial Comparing a Combination of Methotrexate Plus Cyclosporine with Cyclosporine Alone for Prophylaxis of Graft-versus-Host.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion Franck E. Nicolini, Eric Wattel, Anne-Sophie.

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Ronan T. Swords, Steven Coutre, Michael.

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL.

Cold agglutinin disease

Presentation transcript:

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 by Xavier Leleu, Michel Attal, Bertrand Arnulf, Philippe Moreau, Catherine Traulle, Gerald Marit, Claire Mathiot, Marie Odile Petillon, Margaret Macro, Murielle Roussel, Brigitte Pegourie, Brigitte Kolb, Anne Marie Stoppa, Bernadette Hennache, Sabine Bréchignac, Nathalie Meuleman, Beatrice Thielemans, Laurent Garderet, Bruno Royer, Cyrille Hulin, Lotfi Benboubker, Olivier Decaux, Martine Escoffre-Barbe, Mauricette Michallet, Denis Caillot, Jean Paul Fermand, Hervé Avet-Loiseau, and Thierry Facon Blood Volume 121(11):1968-1975 March 14, 2013 ©2013 by American Society of Hematology

IFM 2009-02 flow Diagram. IFM 2009-02 flow Diagram. Xavier Leleu et al. Blood 2013;121:1968-1975 ©2013 by American Society of Hematology

(A-C) Survival end points per 21 of 28-day arm (N = 43) and 28 of 28-day arm (N = 41); Kaplan-Meier estimates (ITT). (A-C) Survival end points per 21 of 28-day arm (N = 43) and 28 of 28-day arm (N = 41); Kaplan-Meier estimates (ITT). (A) Time to progression. (B) Progression-free survival. (C) Overall survival. (D-F) Survival end points in the entire population (N = 84); Kaplan-Meier estimates (ITT). (D) Comparison between TTP on protocol and TTP on last prior line for all patients included in the study and for responders only (patients with either CR or VGPR or PR as per IMWG). (E) TTP In responders versus nonresponders as per IMWG criteria (eg, patients with stable disease including minimal response [SD]). (F) Overall survival in responders versus SD. O/N, number of events/number of patients in the group. Xavier Leleu et al. Blood 2013;121:1968-1975 ©2013 by American Society of Hematology